Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,271 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,666 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07212491 | Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma | enrolling by invitation | — | 450 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07344220 | Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate(DZ-002-201) | enrolling by invitation | Phase 2 | 39 | Hoag Memorial Hospital PresbyterianOTHER | 1 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT00923026 | Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies | enrolling by invitation | — | 1,150 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06910072 | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）(UPGRADE-TNBC) | enrolling by invitation | Phase 2 / Phase 3 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06157671 | The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma | enrolling by invitation | — | 1,000 | Adenocyte, LLCINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07713901 | Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma | enrolling by invitation | — | 93,600,000 | Novo Nordisk A/SINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT00102544 | Use of Tracking Devices to Locate Abnormalities During Invasive Procedures | enrolling by invitation | N/A | 3,894 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07532928 | A Bidirectional Study of Individualized Postoperative Adjuvant Treatment Decision Model for Locally Advanced Head and Neck Squamous Cell Carcinoma Based on Multimodal Dynamic Data | enrolling by invitation | — | 571 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07703735 | Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma(HCC) | enrolling by invitation | — | 371 | Seoung Hoon KimOTHER_GOV | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07139951 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence | enrolling by invitation | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02427269 | University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository(BEECAB) | enrolling by invitation | — | 1,000 | University of North Carolina, Chapel HillOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02600949 | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | enrolling by invitation | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07218003 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | enrolling by invitation | Phase 1 | 149 | Rondo TherapeuticsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07618624 | BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression(BRIDGE) | enrolling by invitation | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07606638 | Effectiveness of Opioid vs Pregabalin Plus Naproxen Sodium in Pain Management of Oral Cancer Patients | enrolling by invitation | N/A | 98 | Mayo Hospital LahoreOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06885424 | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products(DESCENT-1) | enrolling by invitation | — | 400 | A2 Biotherapeutics Inc.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT07595666 | Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region. | enrolling by invitation | N/A | 1,600 | prof. dr. Koen Van LaereOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06782399 | Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma(SCC) | enrolling by invitation | Early Phase 1 | 25 | Oliver JonasOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06862479 | Luso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences(ES-LCCE-UDFM)(ES-LCCE-UDFM) | enrolling by invitation | — | 180 | Unidade Local de Saúde Santa MariaOTHER_GOV | 1 | May 6, 2026 | clinicaltrials |
| NCT07567716 | Infiltration Pattern of Locally Advanced ESCC | enrolling by invitation | — | 30 | Shanghai Chest HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06381882 | The Role of the Human Microbiome in Patients After Pancreatic Resection.(MiPac) | enrolling by invitation | — | 200 | St. Antonius HospitalOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07298577 | Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer(STOPHCC-GAAD) | enrolling by invitation | N/A | 2,100 | Siriraj HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07550972 | Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. | enrolling by invitation | Phase 2 | 30 | Zhejiang Provincial People's HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07533825 | Laparoscopic Staging for Stage III Gastric Cancer(CGCA202501) | enrolling by invitation | N/A | 968 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07488572 | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study | enrolling by invitation | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT00587314 | The Effect of Ablation Therapy on Barrett's Esophagus(ablation IN BE) | enrolling by invitation | — | 600 | Mayo ClinicOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05160480 | A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG | enrolling by invitation | — | 9 | University of California, DavisOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06624189 | Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis | enrolling by invitation | — | 1,300 | NYU Langone HealthOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05441475 | A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients | enrolling by invitation | Phase 2 | 118 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06730685 | Sarcopenia and Cachexia in Patients With Lung Cancer(PHILUCA) | enrolling by invitation | — | 160 | Zealand University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07390565 | YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer | enrolling by invitation | N/A | 308 | LI FENGOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06061328 | Project OASIS: Optimizing Approaches to Select Implementation Strategies(OASIS) | enrolling by invitation | N/A | 8,020 | VA Office of Research and DevelopmentFED | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07376629 | A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC | enrolling by invitation | Phase 2 | 60 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02081755 | Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer | enrolling by invitation | Phase 4 | 336 | Baylor Research InstituteOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07347392 | The Role of Radiotherapy for the Management of Non-melanoma Skin Cancer in Denmark.(DOSCA-2) | enrolling by invitation | — | 2,900 | University of AarhusOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07312578 | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma | enrolling by invitation | Phase 2 | 48 | Peking UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07290764 | Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy | enrolling by invitation | — | 729 | Fujian Provincial HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06843681 | Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study | enrolling by invitation | Phase 2 | 54 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07241676 | Early Recurrence After Surgery for Pancreatic Cancer(POCEMON BLUE) | enrolling by invitation | — | 500 | Azienda Ospedaliera di PadovaOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02270567 | RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide(RegisterNET) | enrolling by invitation | — | 400 | Wren Laboratories LLCINDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT04539717 | FAST (Focused Abbreviated Screening Technique)-MRI Study | enrolling by invitation | — | 820 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT07121478 | Patients With High-grade Pancreatic Neuroendocrine Tumors | enrolling by invitation | Phase 2 | 46 | National Cancer Center, KoreaOTHER_GOV | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06882876 | JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study | enrolling by invitation | Phase 1 | 20 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05385861 | Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET | enrolling by invitation | Phase 1 / Phase 2 | 52 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07101900 | 68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses | enrolling by invitation | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07072676 | The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.(Risk of fall) | enrolling by invitation | N/A | 30 | LMU KlinikumOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07052448 | The Efficacy of Sequential RT After Triple Therapy for uHCC | enrolling by invitation | — | 35 | Fujian Provincial HospitalOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07047937 | Explainable Machine Learning for Predicting Early Gastric Cancer | enrolling by invitation | — | 10 | Wenzhou Central HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07034859 | Cabergoline in the Management of Nonfunctioning Pituitary Adenoma | enrolling by invitation | Phase 4 | 30 | National Taiwan University HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
Data updated 16 hours agoSource updated Sep 29, 2026source: clinicaltrials